Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada.
about
Contribution of exogenous genetic elements to the group A Streptococcus metagenomeInvasive group A streptococcal disease in Alberta, Canada (2000 to 2002).Antimicrobial susceptibility survey of Streptococcus pyogenes isolated in Japan from patients with severe invasive group A streptococcal infectionsPrevalence of polyclonal mefA-containing isolates among erythromycin-resistant group A streptococci in Southern Taiwan.Molecular detection of antimicrobial resistanceResistance to macrolides in Streptococcus pyogenes in France in pediatric patients.Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci.Prevalence and mechanisms of macrolide resistance in Streptococcus pyogenes in Santiago, Chile.Identification of an erm(A) erythromycin resistance methylase gene in Streptococcus pneumoniae isolated in Greece.Macrolide resistance in Peptostreptococcus spp. mediated by ermTR: possible source of macrolide-lincosamide-streptogramin B resistance in Streptococcus pyogenesPrevalence of macrolide resistance genes in clinical isolates of the Streptococcus anginosus ("S. milleri") group.Efficacies of ABT-773, a new ketolide, against experimental bacterial infections.High prevalence of inducible erythromycin resistance among Streptococcus bovis isolates in Taiwan.Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada.Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countriesActivities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000.Resistance determinants and clonal diversity in group A streptococci collected during a period of increasing macrolide resistance.Erythromycin-resistant pharyngeal isolates of Streptococcus pyogenes recovered in ItalyPhenotypic and genotypic characterization of group B streptococcal isolates in southern Brazil.Erythromycin and clindamycin resistance in group B streptococcal clinical isolates.Epidemiologic analysis of invasive and noninvasive group a streptococcal isolates in Hong KongIn vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistanceEvolution and global dissemination of macrolide-resistant group A streptococci.Emergence of macrolide resistance in throat culture isolates of group a streptococci in Ontario, Canada, in 2001.Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E)Clinical and epidemiological aspects of invasive Streptococcus pyogenes infections in Denmark during 2003 and 2004.Resistance of group B streptococcus to selected antibiotics, including erythromycin and clindamycin.Survey of strain distribution and antibiotic resistance pattern of group B streptococci (Streptococcus agalactiae) isolated from clinical specimens.Detection of multiple macrolide- and lincosamide-resistant strains of Streptococcus pyogenes from patients in the Boston area.Emergence of macrolide-resistant Streptococcus pyogenes strains in French children.In vitro activity of solithromycin against erythromycin-resistant Streptococcus agalactiae.Antistreptococcal activity of AR-709 compared to that of other agents.DNA methylase activity as a marker for the presence of a family of phage-like elements conferring efflux-mediated macrolide resistance in streptococci.Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumonPrevalence and mechanisms of erythromycin resistance in group A and group B Streptococcus: implications for reporting susceptibility results.
P2860
Q33295386-E8DB6CCB-85D6-48F4-A6E5-66DAA4FE2E08Q33753352-5BDBB840-676F-4F7A-996C-DAC0F1F2603FQ33804874-9F58055B-9020-4AA8-A839-486B95760CA8Q33968036-1EAA2BC9-93FF-4FA5-8D42-398187B7481CQ33975793-DC81227F-35E9-45A1-A2ED-55B9E2BA8378Q33979617-A288DE94-0FA9-4DE7-BA83-25F5BAEB7C5CQ33979988-8C515800-530D-4012-B274-3ED0B32A1BC1Q33981276-70EF1679-DC72-4897-962E-A2EEA3EADA46Q33981283-AE1B9F01-0C32-4B7A-B46F-0D8C502C4437Q33981515-7AFFBAAB-AD99-42EE-A418-D0B783E3397DQ33982805-9BC83884-55C9-4F78-9AF6-84026C77E0C6Q33982950-8DEBEA56-CACA-42CD-982B-68C053B1E2FBQ33983537-501670C0-7066-43DC-9B57-2900131F6BA9Q33983637-B19BA102-7381-4287-95B1-9C7C2811EF99Q34105515-A2793FF1-A533-413E-A0F5-6F55149B0D87Q34107331-AFAB2AFB-E741-4D00-BEBE-C19D5DC7EF66Q34109184-EABF1E04-AB86-4740-862F-789E2A758CCCQ34251686-87CD0DA2-BB03-4DB4-B876-039CB022C4DDQ34433251-8BBBC9C4-5B34-4E5D-9A12-976B0743843DQ34648661-2589BB39-8EBC-4E6D-93B2-EEE012C07675Q34774612-41DBE325-0DFD-4885-BB43-5F3EF78FE298Q35007097-6C7CF4F1-CB1D-490E-8F10-D367D1C3D217Q35023314-DAA5DA03-3FAE-4B53-B9D0-969801E20F16Q35102373-B4C5274C-F921-4DDF-9E21-517DD1E9371FQ36081307-BC4F88CF-D412-4AF4-BCC1-AB917594FB79Q36423634-DB174475-5A20-422D-A0DA-E7DE9D3C172DQ36599054-52786535-1977-48D9-AD26-BDE0AE81399EQ37254222-8FE0E093-2001-4E58-B1A7-A81645270C68Q37420239-1014BFEA-6949-41F2-A5F4-CB993CA4FC05Q37488762-3170DE95-F42F-48B4-82C1-6BDA7B6E659EQ37643673-14138BFB-F5B1-4320-8AA1-F8693C86EB35Q38898215-7F7AF43D-D76A-4B39-A3A1-C2BDFFA32C01Q39077279-6BE91137-015B-42B7-BEB9-F526F181F5CCQ39478959-666AB366-2EC5-41BA-A979-985993579E4FQ40625576-F3835453-B170-48B5-9D0F-F23FCFE06374
P2860
Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Prevalence and mechanisms of m ...... ptococci from Ontario, Canada.
@ast
Prevalence and mechanisms of m ...... ptococci from Ontario, Canada.
@en
type
label
Prevalence and mechanisms of m ...... ptococci from Ontario, Canada.
@ast
Prevalence and mechanisms of m ...... ptococci from Ontario, Canada.
@en
prefLabel
Prevalence and mechanisms of m ...... ptococci from Ontario, Canada.
@ast
Prevalence and mechanisms of m ...... ptococci from Ontario, Canada.
@en
P2093
P2860
P1476
Prevalence and mechanisms of m ...... ptococci from Ontario, Canada.
@en
P2093
P2860
P304
P407
P577
1999-09-01T00:00:00Z